MS Tech Ltd., a leader in nanotechnology and biotechnology-based detection and diagnostics sensors, has recently been awarded a $1.2 million R&D grant by the Israel Innovation Authority. This grant is aimed at furthering the development of the company's cutting-edge biosensor technology, which is designed for the early detection of disease biomarkers in liquid biopsies. The technology promises to revolutionize early diagnostics by providing fast, point-of-care results, a significant improvement over current laboratory-based methods that are both time-consuming and costly.
The grant recognizes MS Tech's pioneering work in the bio-convergence field, integrating biology, life sciences, engineering, and software to advance its HF-QCM sensor technologies. These innovations have the potential to impact not only medical diagnostics but also sectors such as agriculture, food security, and environmental protection. Doron Shalom, CEO of MS Tech, highlighted the importance of this recognition, stating, 'We are honored that the Israel Innovation Authority once again acknowledges our biosensor technologies as being at the forefront of scientific and technological innovation.'
This development is part of the LIQUIDBX Consortium's efforts to create a technological infrastructure for the early detection of diseases through advanced multi-omic sensors. By combining novel biosensors with artificial intelligence and advanced learning algorithms, the consortium aims to analyze signals across multiple biological elements, offering a comprehensive approach to early disease screening. The integration of IoT capabilities into MS Tech's biosensors enables immediate data-driven decisions, potentially transforming patient care and healthcare provider operations worldwide.
